Biolex Therapeutics Researchers Present Preclinical Data for Direct-Acting Thrombolytic BLX-155 at Scientific Conference

PITTSBORO, NC -- (MARKET WIRE) -- March 01, 2007 -- Biolex Therapeutics researchers presented data at the 51st Annual Congress of the German Society of Thrombosis and Haemostasis Research in Dresden, Germany demonstrating the successful production of full-length recombinant human plasmin (BLX-155) using the Company's proprietary LEX System(SM), a milestone never achieved at commercially viable levels with any existing protein expression system. Plasmin is the key enzyme in the human body that dissolves the fibrin component of blood clots. The development of a recombinant version of plasmin provides a potential best-in-class product profile for the Company's BLX-155 drug candidate.